Enzon Pharmaceuticals, Inc. (ENZN)

Overview

Enzon Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the marketing of drug products. With its foundation laid in 1981, the company has established itself in the pharmaceutical sector, focusing on the development and commercialization of critical care treatments. Headquartered in Cranford, New Jersey, Enzon Pharmaceuticals, Inc. works alongside its subsidiaries to advance its mission of providing innovative therapeutics. The company has built a reputation over the years for its contribution to drug development and marketing, leveraging a combination of research and strategic collaborations to enhance its product offerings.

Products and Services

The company offers a range of pharmaceutical products, primarily focusing on PegIntron and has a marketing agreement for Vicineum. Below are the details of its products:

• PegIntron: PegIntron is Enzon Pharmaceuticals’ marketed drug product. It is a pegylated interferon used primarily for the treatment of hepatitis C. This medication works by stimulating the body's immune system to fight off the virus, providing a significant option for patients battling this chronic condition. PegIntron represents a key aspect of Enzon's product portfolio, demonstrating the company's commitment to addressing infectious diseases through advanced therapeutic solutions.
• Vicineum: While not directly developed by Enzon, the company holds a marketing agreement for Vicineum, a treatment designed for cancer therapy. This collaboration highlights Enzon Pharmaceuticals' strategy to expand its product range through partnerships, emphasizing the company's role in bringing innovative treatments to the market. Vicineum showcases Enzon’s involvement in oncology, aiming to make a positive impact on the lives of patients facing cancer diagnoses.